Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Methods Mol Biol. 2023;2576:67-94. doi: 10.1007/978-1-0716-2728-0_6.
Cannabis plant has been used from ancient times with therapeutic purposes for treating human pathologies, but the identification of the cellular and molecular mechanisms underlying the therapeutic properties of the phytocannabinoids, the active compounds in this plant, occurred in the last years of the past century. In the late 1980s and early 1990s, seminal studies demonstrated the existence of cannabinoid receptors and other elements of the so-called endocannabinoid system. These G protein-coupled receptors (GPCRs) are a key element in the functions assigned to endocannabinoids and appear to serve as promising pharmacological targets. They include CB, CB, and GPR55, but also non-GPCRs can be activated by endocannabinoids, like ionotropic receptor TRPV and even nuclear receptors of the PPAR family. Their activation, inhibition, or simply modulation have been associated with numerous physiological effects at both central and peripheral levels, which may have therapeutic value in different human pathologies, then providing a solid experimental explanation for both the ancient medicinal uses of Cannabis plant and the recent advances in the development of cannabinoid-based specific therapies. This chapter will review the scientific knowledge generated in the last years around the research on the different endocannabinoid-binding receptors and their signaling mechanisms. Our intention is that this knowledge may help readers to understand the relevance of these receptors in health and disease conditions, as well as it may serve as the theoretical basis for the different experimental protocols to investigate these receptors and their signaling mechanisms that will be described in the following chapters.
大麻植物从古至今一直被用于治疗人类疾病的治疗目的,但在上个世纪末才确定了植物大麻素(这种植物中的活性化合物)的治疗特性的细胞和分子机制。在 20 世纪 80 年代末和 90 年代初,重要的研究表明存在大麻素受体和所谓的内源性大麻素系统的其他元素。这些 G 蛋白偶联受体(GPCR)是内源性大麻素所赋予的功能的关键要素,似乎是有前途的药理学靶点。它们包括 CB1、CB2 和 GPR55,但也可以被内源性大麻素激活非 GPCR,如离子型受体 TRPV 甚至核受体 PPAR 家族。它们的激活、抑制或简单的调节与中枢和外周水平的许多生理效应有关,这些效应可能对不同的人类疾病具有治疗价值,从而为大麻植物的古代药用用途和最近在开发基于大麻素的特定疗法方面的进展提供了坚实的实验解释。本章将回顾过去几年围绕不同内源性大麻素结合受体及其信号转导机制的研究产生的科学知识。我们的目的是,这些知识可以帮助读者理解这些受体在健康和疾病状况下的相关性,也可以作为研究这些受体及其信号转导机制的不同实验方案的理论基础,这些方案将在以下章节中描述。